Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2017

Open Access 01-12-2017 | Research article

Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA

Authors: Monika Wagner, Hanane Khoury, Liga Bennetts, Patrizia Berto, Jenifer Ehreth, Xavier Badia, Mireille Goetghebeur

Published in: BMC Cancer | Issue 1/2017

Login to get access

Abstract

Background

The objective of the study was to reveal through pragmatic MCDA (EVIDEM) the contribution of a broad range of criteria to the value of the orphan drug lenvatinib for radioiodine refractory differentiated thyroid cancer (RR-DTC) in country-specific contexts.

Methods

The study was designed to enable comprehensive appraisal (12 quantitative, 7 qualitative criteria) in the current disease context (watchful waiting, sorafenib) of France, Italy and Spain. Data on the value of lenvatinib was collected from diverse stakeholders during country-specific panels and included: criteria weights (individual and social values); performance scores (judgments on evidence—collected through MCDA systematic review); qualitative impacts of contextual criteria; and verbal and written insights structured by criteria. The value contribution of each criterion was calculated and uncertainty explored.

Results

Comparative effectiveness, Quality of evidence (Spain and Italy) and Disease severity (France) received the greatest weights. Four criteria contributed most to the value of lenvatinib, reflecting its superior Comparative effectiveness (16–22% of value), the severity of RR-DTC (16–22%), significant unmet needs (14–21%) and robust evidence (14–20%). Contributions varied by comparator, country and individuals, highlighting the importance of context and consultation. Results were reproducible at the group level. Impacts of contextual criteria varied across countries reflecting different health systems and cultural backgrounds. The MCDA process promoted sharing stakeholders’ knowledge on lenvatinib and insights on context.

Conclusions

The value of lenvatinib was consistently positive across diverse therapeutic contexts. MCDA identified the aspects contributing most to value, revealed rich contextual insights, and helped participants express and explicitly tackle ethical trade-offs inherent to balanced appraisal and decisionmaking.
Appendix
Available only for authorised users
Literature
1.
European Medicines Agency. Product characteristics. Lenvima. 2015.
2.
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621–30.CrossRefPubMed
3.
European Medicines Agency. CHMP assessment report. Lenvima. 2015.
4.
5.
Tuttle RM, Haddad RI, Ball DW, Byrd D, Dickson P, Duh QY, et al. Thyroid carcinoma, version 2.2014. J Natl Compr Cancer Netw. 2014;12(12):1671–80.
6.
7.
Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard BG, et al. Guidelines for the management of thyroid cancer. Clin Endocrinol. 2014;81(Suppl 1):1–122.CrossRef
8.
Dionigi G, Kraimps JL, Schmid KW, Hermann M, Sheu-Grabellus SY, De WP, et al. Minimally invasive follicular thyroid cancer (MIFTC)--a consensus report of the European Society of Endocrine Surgeons (ESES). Langenbeck's Arch Surg. 2014;399(2):165–84.CrossRef
9.
10.
Pacini F, Castagna MG, Brilli L, Pentheroudakis G. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii110–9.CrossRefPubMed
11.
Guerrier B, Berthet JP, Cartier C, Dehesdin D, Edet-Sanson A, Le CG, et al. French ENT society (SFORL) practice guidelines for lymph-node management in adult differentiated thyroid carcinoma. Eur Ann Otorhinolaryngol Head Neck Dis. 2012;129(4):197–206.CrossRefPubMed
12.
13.
Taylor MH, Flores NM, Pelletier C, DiBonaventura M, Forsythe A, Wolfe G. Treatment patterns among patients with radioiodine-refractory differentiated thyroid cancer in the United States and Western Europe. Abstract presented at the 84th Annual Meeting of the American Thyroid Association; 2014. Coronado, California.
14.
15.
16.
17.
Schlander M, Garattini S, Holm S, Kolominsky-Rabas P, Nord E, Persson U, et al. Incremental cost per quality-adjusted life year gained? The need for alternative methods to evaluate medical interventions for ultra-rare disorders. J Comp Eff Res. 2014;3(4):399–422.CrossRefPubMed
18.
19.
Tunis SR. Reflections on science, judgment, and value in evidence-based decision making: a conversation with David Eddy. Health Aff (Millwood ). 2007;26(4):w500–15.CrossRef
20.
Goetghebeur MM, Wagner M, Khoury H, Rindress D, Gregoire JP, Deal C. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for turner syndrome patients. Cost Eff Resour Alloc. 2010;8(1):4.CrossRefPubMedPubMedCentral
21.
Tony M, Wagner M, Khoury H, Rindress D, Papastavros T, Oh P, et al. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada. BMC Health Serv Res. 2011;11:329.CrossRefPubMedPubMedCentral
22.
Wahlster P, Goetghebeur M, Kriza C, Niederlander C, Kolominsky-Rabas P. Balancing costs and benefits at different stages of medical innovation: a systematic review of multi-criteria decision analysis (MCDA). BMC Health Serv Res. 2015;15:262.CrossRefPubMedPubMedCentral
23.
Baeroe K, Baltussen R. Legitimate healthcare limit setting in a real-world setting: integrating accountability for reasonableness and multi-criteria decision analysis. Publ Health Ethics. 2014;7(2):98–111.CrossRef
24.
25.
Goetghebeur MM, Wagner M, Khoury H, Levitt RJ, Erickson LJ, Rindress D. Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal. Med Decis Mak. 2012;32(2):376–88.CrossRef
26.
Wagner M, Khoury H, Willet J, Rindress D, Goetghebeur M. Can the EVIDEM framework tackle issues raised by evaluating treatments for rare diseases: analysis of issues and policies, and context-specific adaptation. PharmacoEconomics. 2016;34(3):285–301.CrossRefPubMed
27.
Busse R, Orvain J, Velasco M, Perleth M. Best practice in undertaking and reporting health technology assessments. Working group 4 report. Int J Technol Assess Health Care. 2002;18(2):361–422.CrossRef
28.
29.
van Til J, Groothuis-Oudshoorn C, Lieferink M, Dolan J, Goetghebeur M. Does technique matter; a pilot study exploring weighting techniques for a multi-criteria decision support framework. Cost Eff Resour Alloc. 2014;12:22.CrossRefPubMedPubMedCentral
30.
Shrout PE, Fleiss JL. Intraclass correlations: uses in assessing rater reliability. Psychol Bull. 1979;86(2):420–8.CrossRefPubMed
31.
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–28.CrossRefPubMedPubMedCentral
32.
Eisai Inc. Indirect treatment comparison: lenvatinib versus sorafenib. Version 2.0 - new data cut. Figure D80.R103.303.2 Kaplan-Meier plot of overall survival adjusted with RPSFT model. Full analysis set. 2015.
33.
Greenblatt DY, Chen H. Palliation of advanced thyroid malignancies. Surg Oncol. 2007;16(4):237–47.CrossRefPubMed
34.
35.
36.
Schvartz C, Dalac A, Ancelle D, Pochart J, Fieffe S, Patey M. Epidemiology of refractory thyroid cancer. Thyroid. 2012;22:A109–10.CrossRef
37.
Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the united states during 1996. U.S. and German thyroid cancer study group. An American College of Surgeons Commission on cancer patient care evaluation study. Cancer. 2000;89(1):202–17.CrossRefPubMed
38.
39.
Kerr C, Fordham B, de Freitas HM, Tremblay G, Johnston K. Health state valuation in radio-iodine refractory differentiated thyroid cancer (RR-DTC). Poster presented at ISPOR 17th Annual European Congress; 2014. Amsterdam.
40.
Berwick DM, Nolan TW, Whittington J. The triple aim: care, health, and cost. Health Aff (Millwood ). 2008;27(3):759–69.CrossRef
41.
42.
Miot J, Wagner M, Khoury H, Anderson AN, Rindress D, Goetghebeur MM. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa. Cost Eff Resour Alloc. 2012;10(1):2.CrossRefPubMedPubMedCentral
43.
Wahlster P, Goetghebeur M, Schaller S, Kriza C, Kolominsky-Rabas P. Exploring the perspectives and preferences for HTA across German healthcare stakeholders using a multi-criteria assessment of a pulmonary heart sensor as a case study. Health Res Policy Syst. 2015;13:24.CrossRefPubMedPubMedCentral
44.
Cleemput I, Castro-Jaramillo H, Goetghebeur M, Thokala P, Tringali M. MCDA for HTA in action: leveraging experience from Europe and Latin America. Panel presented at the Health Technology Assessment International (HTAi) 12th Annual Conference. Oslo, Norway. 2015.
45.
Radaelli G, Lettieri E, Masella C, Merlino L, Strada A, Tringali M. Implementation of EUnetHTA Core model(R) in Lombardia: the VTS framework. Int J Technol Assess Health Care. 2014;30(1):105–12.CrossRefPubMed
46.
Tanios N, Wagner M, Tony M, Baltussen R. Van TJ, Rindress D, et al. which criteria are considered in healthcare decisions? Insights from an international survey of policy and clinical decision makers. Int J Technol Assess Health Care. 2013;29(4):456–65.CrossRefPubMed
47.
Dipankui MT, Gagnon MP, Desmartis M, Legare F, Piron F, Gagnon J, et al. Evaluation of patient involvement in a health technology assessment. Int J Technol Assess Health Care. 2015;31(3):166–70.CrossRefPubMed
48.
Lopes E, Street J, Carter D, Merlin T. Involving patients in health technology funding decisions: stakeholder perspectives on processes used in Australia. Health Expect. 2016;19(2):331–44.CrossRefPubMed
49.
Douglas CM, Wilcox E, Burgess M, Lynd LD. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy. 2015;119(5):588–96.CrossRefPubMed
50.
Menon D, Stafinski T, Dunn A, Short H. Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity? Patient. 2015;8(1):29–39.CrossRefPubMed
51.
Moreira T. Understanding the role of patient organizations in health technology assessment. Health Expect. 2015;18(6):3349–57.CrossRefPubMed
52.
Bernabe RD, van Thiel GJ, van DJ. Patient representatives’ contributions to the benefit-risk assessment tasks of the European medicines agency scientific committees. Br J Clin Pharmacol. 2014;78(6):1248–56.CrossRefPubMedPubMedCentral
53.
Fleurence RL, Forsythe LP, Lauer M, Rotter J, Ioannidis JP, Beal A, et al. Engaging patients and stakeholders in research proposal review: the patient-centered outcomes research institute. Ann Intern Med. 2014;161(2):122–30.CrossRefPubMed
54.
Gagnon MP, Candas B, Desmartis M, Gagnon J, La RD, Rhainds M, et al. Involving patient in the early stages of health technology assessment (HTA): a study protocol. BMC Health Serv Res. 2014;14:273.CrossRefPubMedPubMedCentral
55.
56.
Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, et al. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther. 2016;10:873–84.CrossRefPubMedPubMedCentral
Metadata
Title
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA
Authors
Monika Wagner
Hanane Khoury
Liga Bennetts
Patrizia Berto
Jenifer Ehreth
Xavier Badia
Mireille Goetghebeur
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2017
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-017-3258-9

Other articles of this Issue 1/2017

BMC Cancer 1/2017 Go to the issue

Research article

The role of nature in cancer patients' lives: a systematic review and qualitative meta-synthesis

Research article

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study

Research article

Droplet digital PCR for detection and quantification of circulating tumor DNA in plasma of head and neck cancer patients

Research article

Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b

Research article

Tamoxifen reverses epithelial–mesenchymal transition by demethylating miR-200c in triple-negative breast cancer cells

Research article

Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits